Preview

Современная ревматология

Расширенный поиск

Основы изучения безопасности лекарственных средств. Спектр редких и неожиданных неблагоприятных реакций бисфосфонатов

https://doi.org/10.14412/1996-7012-2011-706

Полный текст:

Аннотация

Представлены классификация и характеристика неблагоприятных реакций (НР) лекарственных средств (ЛС). На примере бисфосфонатов (БФ), которые используются более 30 лет для профилактики и лечения всех форм остеопороза (ОП), признаны препаратами «первой линии» лечения ОП, прослежена история изучения редких и неожиданных НР. На сегодняшний день прямая связь между редкими НР и приемом БФ остается недоказанной. Представляется необоснованным предложение о сокращении назначений БФ. Доказательства эффективности и безопасности БФ при ОП получены и подтверждены многочисленными исследованиями, многолетней реальной практикой. На сегодняшний день самым изученным БФ является алендронат (фосаванс).

Литература

1. <div><p>Осложнения фармакотерапии. Неблагопритяные побочные реакции лекарственных средств. Т. 1. Под ред. Д.В. Рей-харта. М.: Литтерра, 2007;256 с.</p><p>Vere D.W. Drug adverse reactions as masquereders. Adverse Drug React Bull 1976;60:208-11</p><p>Планирование и проведение клинических исследований лекарственных средств. Под ред. Ю.Б. Белоусова. М.: Изд-во Общества клинических исследователей, 2000;579 с.</p><p>Шварц Г.Я. Фармакотерапия остеопороза. М.: МИА, 2002;410 с.</p><p>Davidson M.R. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003;48:39-52.</p><p>Russell R.G., Watts N.B., Ebetino F.H. et al. Mechanisms of actions of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteop Int 2008;19:733-59.</p><p>Nancollas G.H., Tang R., Phipps R.J. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27</p><p>Lawson M.A., Xia Z., Barnett B.L. et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 2009;92B:149-55.</p><p>Риггз Б.Л., Мелтон Л.Д. Остеопороз. Этиология, диагностика, лечение. М.: Би- ном, 2000;558 с.</p><p>Eastell R. Treatment of Postmenopausal Osteoporosis. N Engl Med J 1998;338(11):736-46.</p><p>Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100</p><p>Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.</p><p>Boivin G.Y., Chavassieux P.M., Santora A.C. et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27(5):687-94.</p><p>Mashiba T., Turner C.H., Hirano T. et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28(5):524-31.</p><p>Recker R., Ensrud K., Diem S. et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004;19:45.</p><p>Black D.M., Schwartz A.V., Ensrud K.E. et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.</p><p>Recker О.Р., Weinstein R.S., Chesnut C.H. 3rd et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteop Int 2004;15(3):231-7.</p><p>Recker О.Р., Delmas P.D., Halse J. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008;23(1):6-16.</p><p>Chesnut C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittenly on fracture risk in post-menopausal osteoporosis. J Bone and Mineral Research 2004;19:1241-9.</p><p>Rodan G., Reszka A., Golub E. et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20(8):1291-300.</p><p>Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties J Bone Miner Res 1999;14:1768-78.</p><p>Baroutsou B., Babiolakis D., Stamatiadou A. et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann Rheum Dis 2004;63(Suppl. 1):455(SATO240</p><p>Simon J.A., Lewiecki E.M., Smith M.E. et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, cross-over study. Clin Ther 2002;24:1871-86.</p><p>Kendler D., Kung A.W., Fuleihan G.H. et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-51.</p><p>Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60.</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly iban-dronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21(12):1895-903.</p><p>Hamilton B., McCoy K., Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteop Int 2003;14:259-62.</p><p>Solomon D.H., Avorn J., Katz J.N. et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-9.</p><p>Lanza F., Sahba B., Schwartz H. et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002;97(1):58-64.</p><p>Cryer B., Miller P., Petruschke R.A. et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2005;21(5):599-607.</p><p>Lanza F.L., Rack M.F., Li L. et al. Placebo-controlled, randomized, evaluatorblinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. 2001;2:S227.</p><p>MacLean C., Newberry S., Maglione M. et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148(3):197-213.</p><p>Halkin H., Dushenat M., Silverman B. et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007;41(1):29-34.</p><p>Valean S., Petrescu M., Catinean A. et al. Pill esophagitis. Rom J Gastroenterol 2005;14(2):159-63</p><p>Fernandes P., Pires M., Gouvea A. Ulcerative esophagitis associated with the use of alendronate sodium: histopathological and endoscopic features. Arq Gastroenterol 2002;39(3):173-6.</p><p>Girelli C., Reguzzoni G., Rocca F. Alendronate-induced esophagitis. A report of 2 cases. Recenti Prog Med 1997;88(5):223-5.</p><p>Toth E., Fork F., Lindelöw K. et al. Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports. Lakartidningen 1998;95(35):3676-80</p><p>Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47(8):1665-78.</p><p>Каратеев А.Е. Лечение бисфосфонатами и патология пищевода. Совр ревматол 2010;3:72-8.</p><p>Bauer D., Black D., Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160(4):517-25.</p><p>De Groen P., Lubbe D., Hirsch L. et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.</p><p>Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(1):89-90.</p><p>Shaheen N.J. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17):1790-1.</p><p>Siris E.S., Oster M.W., Bilezikian J.P. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17):1791.</p><p>Abrahamsen B. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17):1789.</p><p>Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17):1789-90.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007;356:1809-22.</p><p>http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm150837.htm</p><p>&lt;http://www.accessdata.fda.gov/drugsatf-&gt;da_docs/label/2009/021817s003lbl.pdf</p><p>&lt;http://www.fda.gov/Safety/MedWatch/&gt; SafetyInformation/SafetyAlertsforHumanMe dicalProducts/ucm079352.htm</p><p>Sorensen H.T., Christensen S., Mehnert F. et al. Use of bisphosphonates among women and risk оf atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-6.</p><p>Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Int Med 2009;265:581-92.</p><p>Mak A. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskeletal Dis 2009;10:113.</p><p>http://www.biomedcentral.com/con-tent/pdf/1471-2474-10-113.pdf</p><p>Black D.M., Cummings S.R., Karpf Db et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.FIT Research Group. Lancet 1996;348:1535-54.</p><p>Mavrokokki T., Cheng A., Stein B. et al. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23.</p><p>Felsenberg D., Hoffmeister B., Amling M. et al. Kiefemekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arzebl 2006;103:3078-81.</p><p>Sook-Bin W., Hellstein J.W., Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006;144:753-61.</p><p>Yoneda T., Hagino H., Sugimoto T. et al. Bisphosphonaterelated osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Jpanese society of oral and maxillofacial surgeons. J Bone Miner Metab, published online 24.03.2010 DOI 10.1007/ s00774-010-0162-7.</p><p>Pazians M., Blumentals W.A., Miller P.D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteop Int 2008;19:773-9.</p><p>Ing-Lorenzini K., Desmeules J., Plachta O. et al. Low-energy femoral fractures associated with the longterm use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32:775-85.</p><p>Burr D.B., Diab T., Koivunemi A. et al. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 2009;27(10):1288-92.</p><p>Biswas P.N., Wilton L.W., Shakir S.A. Pharmacovigilance study of alendronate in England. J Osteop Int 2003;14:507-14.</p><p>Leung S., Ashar B.H., Miller R.G. Bisphosphonate-associated scleritis: a case report and review. South Med 2005;98:733-5.</p></div><br />


Для цитирования:


Дыдыкина И.С., Дыдыкина П.С., Муравьев Ю.В. Основы изучения безопасности лекарственных средств. Спектр редких и неожиданных неблагоприятных реакций бисфосфонатов. Современная ревматология. 2011;5(4):79-86. https://doi.org/10.14412/1996-7012-2011-706

For citation:


Dydykina I.S., Dydykina P.S., Muravyev Y.V. Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates. Modern Rheumatology Journal. 2011;5(4):79-86. (In Russ.) https://doi.org/10.14412/1996-7012-2011-706

Просмотров: 702


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)